ACRV News

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

Archie Ai Introduces Local AI Model for Realtors, Bringing Listing and Marketing Help to Their Computers

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Form 8-K

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Form 8-K